Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways
about
B cell maturation protein is a receptor for the tumor necrosis factor family member TALL-1SIKE is an IKK epsilon/TBK1-associated suppressor of TLR3- and virus-triggered IRF-3 activation pathwaysTNAP, a novel repressor of NF-kappaB-inducing kinase, suppresses NF-kappaB activationGIDE is a mitochondrial E3 ubiquitin ligase that induces apoptosis and slows growthStaphylococcus aureus - induced tumor necrosis factor - related apoptosis - inducing ligand expression mediates apoptosis and caspase-8 activation in infected osteoblastsIrradiation specifically sensitises solid tumour cell lines to TRAIL mediated apoptosisSurface TRAIL decoy receptor-4 expression is correlated with TRAIL resistance in MCF7 breast cancer cellsMembrane trafficking of death receptors: implications on signallingIn chronic pancreatitis, widespread emergence of TRAIL receptors in epithelia coincides with neoexpression of TRAIL by pancreatic stellate cells of early fibrotic areasFollowing a TRAIL: update on a ligand and its five receptorsThe short splice form of Casper/c-FLIP is a major cellular inhibitor of TRAIL-induced apoptosis.TAK1 is required for survival of mouse fibroblasts treated with TRAIL, and does so by NF-kappaB dependent induction of cFLIPL.NF-κB targeting by way of IKK inhibition sensitizes lung cancer cells to adenovirus delivery of TRAIL.Reovirus infection activates JNK and the JNK-dependent transcription factor c-Jun.Apoptosis modulates protective immunity to the pathogenic fungus Histoplasma capsulatumThe death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase.MEKK1-MKK4-JNK-AP1 pathway negatively regulates Rgs4 expression in colonic smooth muscle cellsCD40 ligand (CD154) and tumour necrosis factor-related apoptosis inducing ligand (Apo-2L) in haematological malignancies.Tumor necrosis factor-related apoptosis-inducing ligand induces caspase-dependent interleukin-8 expression and apoptosis in human astroglioma cells.TRAIL in cancer therapy: present and future challenges.MicroRNA-140 acts as a liver tumor suppressor by controlling NF-κB activity by directly targeting DNA methyltransferase 1 (Dnmt1) expression.Positive cross-talk between estrogen receptor and NF-kappaB in breast cancer.T cells require tumor necrosis factor-alpha to provide protective immunity in mice infected with Histoplasma capsulatum.TRAIL/Apo-2L: mechanisms and clinical applications in cancer.NF-kappaB and FLIP in arsenic trioxide (ATO)-induced apoptosis in myelodysplastic syndromes (MDSs)Expression of TRAIL-splice variants in gastric carcinomas: identification of TRAIL-γ as a prognostic marker.Eliminating established tumor in nu/nu nude mice by a tumor necrosis factor-alpha-related apoptosis-inducing ligand-armed oncolytic adenovirus.The TRAIL to viral pathogenesis: the good, the bad and the uglyIsolation of a TRAIL antagonist from the serum of HIV-infected patients.The role of TRAIL in mediating autophagy in myositis skeletal muscle: a potential nonimmune mechanism of muscle damageDeletion of Chromosomal Region 8p21 Confers Resistance to Bortezomib and Is Associated with Upregulated Decoy TRAIL Receptor Expression in Patients with Multiple Myeloma.Osteoprotegerin Prevents Development of Abdominal Aortic AneurysmsInduction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells.Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation.TRAIL, caspases and maturation of normal and leukemic myeloid precursors.Targeting TNF-related apoptosis-inducing ligand (TRAIL) receptor by natural products as a potential therapeutic approach for cancer therapyDifferential activation of JNK1 isoforms by TRAIL receptors modulate apoptosis of colon cancer cell lines.Life and death by death receptors.Bortezomib enhances antigen-specific cytotoxic T cell responses against immune-resistant cancer cells generated by STAT3-ablated dendritic cells.Combined modality therapy with TRAIL or agonistic death receptor antibodies.
P2860
Q22254659-8DBE8643-8A05-422A-B476-78CFA8D84253Q24294536-F17910A2-022E-4F25-868A-29D5622B8B54Q24297399-FBB94C48-55CC-4FF7-91C0-6469B44B9C3AQ24308802-077EE752-9A72-4E17-BEBB-A23474B1B121Q24794331-D8445AE9-64D3-4003-B92F-83E81C410989Q24798681-68773097-612D-4A47-92BF-842875B75823Q24810732-B72A87D6-8E82-4E0C-BE71-4DDE64A3B696Q26852802-423A5C22-C528-423C-82FB-50E61AE3BF19Q28179380-4349E2B5-477F-412A-9839-FB72D34474B9Q28292767-EB0814CD-31CE-4035-BEB1-9730ED39A718Q32051074-5F847616-C60F-494A-BD0D-ACE455E0CC45Q33523025-ECCA4889-9EFA-4A45-A5AA-35649B237E1CQ33729242-4536F1E0-FF91-4148-841B-5F5CA9750ECCQ33849552-0A5BBFDD-BA04-48F0-AC28-E9AEF34EF882Q33942647-7D4D3961-0A31-485B-BDE3-25905E295B4AQ33965358-6AB26D4D-229F-49CC-B2A0-27DE1BDEC9EBQ34251193-71A2FBCF-C611-4B37-8990-D47C4D38E04FQ34266298-0802E6CF-CA10-4B9C-8415-32064B9AB8F8Q34272896-6198CF92-C02A-43A6-8716-96787FB145A9Q34291312-4F83573E-039A-4563-8297-3C0D8B0D2EA6Q34294469-6D454036-5505-4E40-9E1C-8423693748CFQ34374852-1E0939F1-D532-4955-BADA-E33BE8EFB827Q34427249-8A5F49B1-9DE9-4EA4-BFAC-2825C48BCAD5Q34482821-B6711F68-BF33-41D5-87F2-B3B3712D3917Q34560200-83B95840-7B67-4A12-B661-7768281671C8Q34929094-AB60B8BA-A006-4BC8-B191-61C41A951DC9Q35100683-A2D743BC-6665-4E8A-8ABE-FFACE5B22A41Q35146349-CCB83FA6-3C4C-4F23-B4A6-AFD24152D36AQ35372514-1D1122A4-964A-44B3-AA75-4960B9C4C50BQ35464924-284D54AA-9345-48E8-B324-68802845464FQ35778422-0D5285B7-A7E0-47EC-AB75-BC4D1F427EDEQ35897444-950CF662-2239-4884-B124-A2A27BF19DA8Q35916207-F1D6D5A3-8D13-4328-BD28-C64505998AB4Q36369402-68F92A0A-CE23-4B16-8A12-CB6124BB0CCAQ36590964-170D1BF7-46ED-439E-952B-4FFAC2D9FFF6Q37071019-63011A6D-ADAB-4024-B9AB-D5A062883F6CQ37222625-42A76B31-29C7-47CB-AB0B-E758066F3671Q37233180-B9DD2EEF-9EF7-4926-B9A7-8618804E9EEAQ37280039-97F1225E-4D6D-40B9-B6D9-DFB69404D404Q37832083-CF1BB9CD-73F2-4E29-96D6-5636350FB9F5
P2860
Tumor necrosis factor-related apoptosis-inducing ligand receptors signal NF-kappaB and JNK activation and apoptosis through distinct pathways
description
1999 nî lūn-bûn
@nan
1999 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Tumor necrosis factor-related ...... osis through distinct pathways
@ast
Tumor necrosis factor-related ...... osis through distinct pathways
@en
Tumor necrosis factor-related ...... osis through distinct pathways
@nl
type
label
Tumor necrosis factor-related ...... osis through distinct pathways
@ast
Tumor necrosis factor-related ...... osis through distinct pathways
@en
Tumor necrosis factor-related ...... osis through distinct pathways
@nl
prefLabel
Tumor necrosis factor-related ...... osis through distinct pathways
@ast
Tumor necrosis factor-related ...... osis through distinct pathways
@en
Tumor necrosis factor-related ...... osis through distinct pathways
@nl
P2093
P3181
P356
P1476
Tumor necrosis factor-related ...... osis through distinct pathways
@en
P2093
P304
P3181
P356
10.1074/JBC.274.43.30603
P407
P577
1999-10-22T00:00:00Z